News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
232,123 Results
Type
Article (5092)
Company Profile (24)
Press Release (227007)
Multimedia
Podcasts (2)
Webinars (4)
Section
Business (82253)
Career Advice (463)
Deals (15054)
Drug Delivery (8)
Drug Development (19079)
Employer Resources (30)
FDA (3683)
Job Trends (3909)
News (120191)
Policy (7515)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (293)
Accelerated approval (6)
Adcomms (4)
Allergies (14)
Alliances (14813)
ALS (38)
Alzheimer's disease (297)
Antibody-drug conjugate (ADC) (41)
Approvals (3783)
Artificial intelligence (83)
Autoimmune disease (28)
Automation (6)
Bankruptcy (97)
Best Places to Work (2865)
Biosimilars (32)
Biotechnology (23)
Bladder cancer (34)
Brain cancer (7)
Breast cancer (102)
Cancer (890)
Cardiovascular disease (62)
Career advice (395)
Career pathing (3)
CAR-T (64)
CDC (2)
Cell therapy (167)
Cervical cancer (5)
Clinical research (16696)
Collaboration (358)
Compensation (374)
Complete response letters (8)
COVID-19 (311)
CRISPR (13)
C-suite (342)
Cystic fibrosis (28)
Data (1333)
Denatured (1)
Depression (21)
Diabetes (79)
Diagnostics (2118)
Digital health (10)
Diversity (1)
Diversity, equity & inclusion (13)
Drug discovery (33)
Drug pricing (14)
Drug shortages (2)
Duchenne muscular dystrophy (37)
Earnings (42766)
Editorial (5)
Employer branding (6)
Employer resources (32)
Events (39149)
Executive appointments (427)
FDA (4423)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (344)
Gene editing (24)
Generative AI (6)
Gene therapy (104)
GLP-1 (145)
Government (424)
Guidances (197)
Healthcare (5047)
HIV (11)
Huntington's disease (5)
IgA nephropathy (11)
Immunology and inflammation (39)
Immuno-oncology (8)
Indications (17)
Infectious disease (337)
Inflammatory bowel disease (36)
Inflation Reduction Act (3)
Influenza (6)
Intellectual property (32)
Interviews (53)
IPO (7880)
IRA (3)
Job creations (1122)
Job search strategy (361)
JPM (4)
Kidney cancer (10)
Labor market (10)
Layoffs (106)
Leadership (5)
Legal (2337)
Liver cancer (21)
Longevity (2)
Lung cancer (96)
Lymphoma (70)
Machine learning (3)
Management (10)
Manufacturing (142)
MASH (50)
Medical device (3919)
Medtech (3929)
Mergers & acquisitions (7584)
Metabolic disorders (219)
Multiple sclerosis (18)
NASH (6)
Neurodegenerative disease (54)
Neuropsychiatric disorders (12)
Neuroscience (543)
NextGen: Class of 2026 (1674)
Non-profit (731)
Now hiring (5)
Obesity (88)
Opinion (32)
Ovarian cancer (26)
Pain (26)
Pancreatic cancer (38)
Parkinson's disease (50)
Partnered (6)
Patents (53)
Patient recruitment (99)
Peanut (6)
People (25227)
Pharmaceutical (7)
Pharmacy benefit managers (2)
Phase 1 (4996)
Phase 2 (7232)
Phase 3 (5790)
Pipeline (1993)
Policy (17)
Postmarket research (625)
Preclinical (1946)
Press Release (66)
Prostate cancer (57)
Psychedelics (3)
Radiopharmaceuticals (109)
Rare diseases (181)
Real estate (1887)
Recruiting (8)
Regulatory (5544)
Reports (17)
Research institute (309)
Resumes & cover letters (69)
Rett syndrome (19)
RNA editing (1)
RSV (2)
Schizophrenia (49)
Series A (53)
Series B (57)
Sickle cell disease (10)
Special edition (1)
Spinal muscular atrophy (33)
Sponsored (5)
Startups (1017)
Stomach cancer (1)
Supply chain (13)
Tariffs (7)
The Weekly (1)
Vaccines (80)
Venture capital (9)
Weight loss (30)
Women's health (6)
Date
Today (29)
Last 7 days (179)
Last 30 days (532)
Last 365 days (8931)
2026 (880)
2025 (9036)
2024 (11034)
2023 (13196)
2022 (18661)
2021 (19680)
2020 (18242)
2019 (13207)
2018 (10205)
2017 (10004)
2016 (9160)
2015 (12119)
2014 (9587)
2013 (7707)
2012 (8329)
2011 (8796)
2010 (8634)
Location
Africa (186)
Alabama (19)
Alaska (2)
Arizona (74)
Arkansas (1)
Asia (11800)
Australia (1691)
California (3556)
Canada (1144)
China (171)
Colorado (145)
Connecticut (163)
Delaware (71)
Europe (25504)
Florida (544)
Georgia (67)
Idaho (24)
Illinois (162)
India (16)
Indiana (107)
Iowa (9)
Japan (167)
Kansas (36)
Kentucky (17)
Louisiana (8)
Maine (51)
Maryland (353)
Massachusetts (2826)
Michigan (104)
Minnesota (202)
Mississippi (1)
Missouri (32)
Montana (17)
Nebraska (12)
Nevada (46)
New Hampshire (16)
New Jersey (1028)
New Mexico (5)
New York (817)
North Carolina (483)
North Dakota (4)
Northern California (1867)
Ohio (116)
Oklahoma (5)
Oregon (6)
Pennsylvania (601)
Puerto Rico (2)
Rhode Island (19)
South America (279)
South Carolina (17)
Southern California (1306)
Tennessee (63)
Texas (486)
United States (12405)
Utah (111)
Virginia (85)
Washington D.C. (17)
Washington State (297)
West Virginia (2)
Wisconsin (58)
Wyoming (1)
232,123 Results for "yuhan corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Ubix Therapeutics and Yuhan Announce Exclusive License Agreement for UBX-103, an Oral Small Molecule AR Degrader for Treatment of Metastatic Castration Resistant Prostate Cancer
Ubix Therapeutics, Inc., a biotechnology company discovering and developing innovative oncology therapeutics based on targeted protein degradation (TPD), announced today that it has entered into an exclusive license agreement with Yuhan to develop and commercialize preclinical androgen receptor (AR) degrader program, UBX-103.
July 1, 2024
·
2 min read
Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug Candidate targeting HER2 NSCLC
Yuhan Corporation announced on the 30th of May that it has signed an in-license agreement with J INTS BIO for a Tyrosine Kinase Inhibitor targeting HER2, ‘JIN-A04'.
May 31, 2023
·
1 min read
Press Releases
Santhera Appoints Stifel as Corporate Finance Advisor
February 10, 2026
·
2 min read
Press Releases
Lyra Therapeutics Provides Corporate Update
January 12, 2026
·
4 min read
Press Releases
Skye Provides 2026 Corporate Outlook
January 12, 2026
·
8 min read
Press Releases
Kiniksa Pharmaceuticals Provides Corporate Update
January 12, 2026
·
11 min read
Press Releases
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
January 13, 2026
·
7 min read
Press Releases
Mereo BioPharma Provides Corporate Update
January 12, 2026
·
9 min read
Press Releases
Humanetics Corporation to Present at Upcoming February 2026 Investor Conference
February 3, 2026
·
1 min read
Press Releases
IO Biotech Provides Corporate Update - January 30, 2026
February 1, 2026
·
2 min read
1 of 23,213
Next
